» Articles » PMID: 39096393

A F-FDG PET/CT Based Radiomics Nomogram for Predicting Disease-free Survival in Stage II/III Colorectal Adenocarcinoma

Overview
Publisher Springer
Date 2024 Aug 3
PMID 39096393
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study aimed to establish a clinical nomogram model based on a radiomics signatures derived from F-fluorodeoxyglucose positron-emission tomography (F-FDG PET/CT) and clinical parameters to predict disease-free survival (DFS) in patients with stage II/III colorectal adenocarcinoma. Understanding and predicting DFS in these patients is key to optimizing treatment strategies.

Methods: A retrospective analysis included 332 cases from July 2011 to July 2021 at The Sixth Affiliated Hospital, Sun Yat-sen University, with PET/CT assessing radiomics features and clinicopathological features. Univariate Cox regression, the least absolute shrinkage and selection operator (LASSO) Cox, and multivariable Cox regression identified recurrence-related radiomics features. We used a weighted radiomics score (Rad-score) and independent risk factors to construct a nomogram. Evaluation involved time-dependent receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).

Results: The nomogram, incorporating Rad-score, pN, and pT demonstrated robust predictive ability for DFS in stage II/III colorectal adenocarcinoma. Training cohort areas under the curve (AUCs) were 0.78, 0.80, and 0.86 at 1, 2, and 3 years, respectively, and validation cohort AUCs were 0.79, 0.75, and 0.73. DCA and calibration curves affirmed the nomogram's clinical relevance.

Conclusion: The F-FDG PET/CT based radiomics nomogram, including Rad-score, pN, and pT, effectively predicted tumor recurrence in stage II/III colorectal adenocarcinoma, significantly enhancing prognostic stratification. Our findings highlight the potential of this nomogram as a guide for clinical decision making to improve patient outcomes.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Hari D, Leung A, Lee J, Sim M, Vuong B, Chiu C . AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment?. J Am Coll Surg. 2013; 217(2):181-90. PMC: 4657944. DOI: 10.1016/j.jamcollsurg.2013.04.018. View

3.
Wu X, Zhang J, He X, Wang C, Lian L, Liu H . Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg. 2011; 16(3):646-55. DOI: 10.1007/s11605-011-1682-8. View

4.
Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3):329-359. DOI: 10.6004/jnccn.2021.0012. View

5.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K . Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(10):1139-1167. DOI: 10.6004/jnccn.2022.0051. View